

## Environmental and Social Data Sheet

### Overview

Project Name:	FERRER PHARMACEUTICAL RDI III
Project Number:	2020-0577
Country:	Spain
Project Description:	The project covers the promoter's R&D activities in a number of well-defined therapeutic areas. The promoter is an innovative pharmaceutical company which is also actively engaged in the response to COVID-19, working collaboratively across the research and healthcare communities to tackle the outbreak.
EIA required:	no
Project included in Carbon Footprint Exercise <sup>1</sup> :	no

### Environmental and Social Assessment

#### Environmental Assessment

The object of the proposed project consists of a selected portfolio amongst Ferrer's EU-based R&D activities, mainly located at the company's R&D centre in Saint Cugat del Valles (Spain) from 2021 up to and including 2024. The activities are focused on the following therapeutic areas: central nervous system (CNS), pain, pulmonary arterial hypertension, chronic obstructive pulmonary diseases, and coronary, atherosclerotic vascular diseases. The project does not entail any capital expenditures. The project's R&D activities are a central part of the promoter's operations and will be embedded in the existing organisational and management structure. The project will not result in any residual environmental impact, as it will be carried out in existing and authorised research facilities, for which all the necessary permits have been received. The operating procedures are in line with best industry standards and are regularly audited by official certifying agencies.

The promoter utilises an environmental management system and safety programmes and is conducting its business in compliance with all applicable environmental laws and regulations. It is certified according to ISO 14001:2015 Environmental Management Systems.

All the production and quality control (QC) activities in Ferrer's manufacturing sites are carried out under Good Manufacturing Practice (GMP) guidelines or equivalent guidelines for non-medicinal products. Likewise, the distribution activities in Ferrer's warehouse are carried out under Good Distribution Practice (GDP) guidelines. Ferrer's sites located in the EU are routinely inspected for GMP by the relevant EU health authorities as well as by the relevant

<sup>1</sup> Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO<sub>2</sub>e/year absolute (gross) or 20,000 tonnes CO<sub>2</sub>e/year relative (net) – both increases and savings.

non-EU health authorities in those cases where a country has its own GMP guidelines and certification inspectorate. Ferrer's sites located in third countries are routinely inspected by the relevant local health authorities and by the relevant health authorities in those cases where a country has its own GMP guidelines and certification inspectorate.

The promoter has shared with the Bank the latest inspection report of the *Servei de Control Farmacèutic i Productes Sanitaris de la Subdirecció General d'Ordenació i Qualitat Sanitàries i Farmacèutiques*, issued by the Catalanian Department of Health, issued in April 2019. No irregularities or specific issues for safety and environmental concerns have been observed.

### **Other Environmental and Social Aspects**

Ferrer aims to foster employment market insertion for the local population and for people with disabilities or who are at risk of social exclusion. Provided the task allows for it, Ferrer collaborates with companies that have a policy of integration of people with disabilities and that have availability of collaborators from a special employment centre, be it in-house or externally. Ferrer collaborates with three special employment centres (Laboratorio DAU, Fundació ASPRONIS and BIBLOX) as well as a further two companies linked to special employment centres (ISS, which is linked to GELIM, and EULEN, which is linked to MISMA EFICACIA).

Ferrer has integrated environmental sustainability into its business model. In 2015, the company launched the "Our planet, Our life" sustainability strategy with the objective of carrying out its activities by means of the sustainable management of natural resources, by minimising environmental footprint throughout the different life cycle stages, by boosting eco-innovation and by spearheading a process of change towards a model of circular economy.

## **Conclusions and Recommendations**

The project activities are not listed in any annexes of the Directive 2014/52/EU amending the EIA Directive 2011/92/EU and will be carried out in existing facilities already authorised that will not change their scope due to the project. As such, the project is acceptable for financing in environmental and social terms.